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Abstract
Although more than 2,400 genes have been shown to contain variants that cause Mendelian disease, there are still several
thousand such diseases yet to be molecularly defined. The ability of new whole-genome sequencing technologies to rapidly
indentify most of the genetic variants in any given genome opens an exciting opportunity to identify these disease genes.
Here we sequenced the whole genome of a single patient with the dominant Mendelian disease, metachondromatosis
(OMIM 156250), and used partial linkage data from her small family to focus our search for the responsible variant. In the
proband, we identified an 11 bp deletion in exon four of PTPN11, which alters frame, results in premature translation
termination, and co-segregates with the phenotype. In a second metachondromatosis family, we confirmed our result by
identifying a nonsense mutation in exon 4 of PTPN11 that also co-segregates with the phenotype. Sequencing PTPN11 exon
4 in 469 controls showed no such protein truncating variants, supporting the pathogenicity of these two mutations. This
combination of a new technology and a classical genetic approach provides a powerful strategy to discover the genes
responsible for unexplained Mendelian disorders.
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Introduction
Elucidation of the molecular bases of Mendelian disease has
provided a rich resource for understanding genetic mechanisms,
protein functions, the behavior of biological systems and
mechanisms of disease [1–3]. Despite intense efforts with a variety
of approaches, however, human geneticists have so far identified
only ,2,400 genes responsible for Mendelian phenotypes, or
about 11% of the total number of protein coding genes in our
genome. Currently, OMIM, a catalog of Mendelian disorders [4],
lists .1,500 mapped Mendelian disorders for which the gene has
yet to be identified, and practicing clinical geneticists know that
there is an untold number of families with Mendelian disorders for
which a molecular explanation or even clear mapping information
has yet to be accomplished. Challenges that prevent harvesting this
trove of biomedical information include the rarity of each disorder,
small family sizes, reduced reproductive fitness of affected
individuals, locus heterogeneity and diagnostic tools that query
only a fraction of all biological systems [1–3,5,6].
The recent development of massively parallel DNA sequencing
technologies has reduced the cost and increased the throughput of
large-scale sequencing (LSS) and provides a new and potentially
powerful way to identify virtually all of the mutations responsible
for Mendelian disorders [7]. Indeed, at least two groups have used
LSS coupled with hybridization strategies to ‘‘capture’’ the
majority of known exons (the ‘‘exome’’) for protein coding genes
to identify genes responsible for three Mendelian disorders [6,8,9].
While there are many good reasons to use whole-exome
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  3sequencing (WES), including the lower cost (currently ,5-fold)
and the fact that exon variation is the most readily interpreted, it is
also clear that WES will miss mutations of interest, including those
variants that are either in exons that are not captured, are in non-
exonic regulatory regions, or are structural variants. At least 1.4%
of the disease variants listed in the Human Gene Mutation
Database ,http://www.hgmd.cf.ac.uk/ac/index.php. are in
regulatory sequences and this is likely to be an underestimate
given the traditional strategies used for mutation detection (largely
PCR amplification and sequencing of exons). The same database
lists about 7.5% of disease variants as structural variants. WES also
requires higher average coverage levels than WGS, both because
of the variable success of capturing different regions and because
of ‘‘allelic imbalance’’ where one allele is preferentially captured
over the other. For these reasons we elected to employ a WGS
strategy.
Both WES and WGS identify a large number of sequence
variants when compared to the reference sequence, making it
important to prioritize variants. This can be based upon both the
assessment of the likelihood of the variants being functional,
especially in the WGS setting (Shianna et al. submitted), and on
their frequency in healthy control populations. These approaches
were used in the WES study that discovered the gene for Miller
syndrome (OMIM 263750) by identifying functional mutations in
the same gene in each of four unrelated patients and no controls
(6). In addition to these approaches, it also is possible to utilize
classical genetic strategies that depend on family structure and
inheritance patterns to prioritize certain genomic regions. In our
case, we show that it is possible to combine partial linkage
information with other criteria for prioritizing variants to identify
the genetic basis of a rare autosomal dominant disorder
(metachondromatosis, OMIM 156250).
The condition we have studied, metachondromatosis (MC,
OMIM 156250), is an autosomal dominant condition character-
ized by exostoses, commonly of the bones of the hands and feet,
and enchondromas of the metaphyses of long bones and iliac crest.
It was first described by Maroteaux in 1971, based on clinical
observation of the six affected individuals from two families [10].
Shortly thereafter, Lachman reported a young male with
enlarging, painless, hard lumps on multiple fingers with concur-
rent long bone metaphyseal and iliac irregularities, both proven by
histopathology to be classic exostoses and enchondroma, respec-
tively [11]. The enchondromas often have a ‘‘striated’’ appearance
in radiographs, and in MC both types of lesions typically appear in
childhood and may regress or even resolve over several years
[10,11] (Figure 1). This phenomenon likely contributes to the
incomplete penetrance that has been described in MC families
[11,12]. The exostoses of MC differ in location, orientation and
duration from those observed in a related set of phenotypes known
as the hereditary multiple exostoses syndromes (MES I and II,
OMIM 133700 and 133701). The exostoses of MESs rarely
resolve and can cause permanent deformity [11–13]. The
osteochondromas of MESs typically point away from the adjacent
epiphysis and rarely affect the hands or feet, while those of MC
point toward the epiphyses and usually present on the hands and
feet [11,13]. Though palpable, the exostoses of MC may not be
calcified and therefore may be radiolucent [14], in part depending
on the timing of the clinical exam and radiography in the lifespan
of a given lesion. The enchondromas of MC are similar to those of
Ollier disease (OMIM 166000, also known as multiple enchon-
dromatosis) but the latter disorder usually lacks exostoses.
Mutations in EXT1 and EXT2, located respectively at 8q24 and
11p11–p12, have been identified in 70% of MES cases [15].
Results
Linkage data
At the outset of our studies, we had access to a single MC family
(Pedigree 1) and had not personally examined individual III-1,
who was reported to be unaffected. We performed linkage analysis
using multiple individuals from Pedigree 1 (Figure 2A) and found
six regions with positive LOD scores. Three of these had LOD
scores of 1.8 or higher: one at 7p14.1 (39.5–43.1 Mb) showed
complete linkage and a LOD of 2.5 (the maximum possible in this
family, resulting from perfect co-segregation); two more, 8q24.1
(129.3–141.2 Mb) and 12q23 (106.0–116.4 Mb), were each
consistent with one non-penetrant individual and a LOD score
of 1.8. Three other regions had LOD scores between 1.0 and 1.5;
one was at 2p25 (3.9–10.0 Mb), one at 5q12.1 (60.6–62.5 Mb) and
one at 9q31.1–q33.1 (111.1–119.3). We considered these six
regions as showing suggestive evidence for the presence of a causal
variant, and therefore concentrated attention on the approxi-
mately 42 Mb (767 Kb exonic) of included sequence.
Evaluation of sequence data
We performed WGS on a single patient (V-1) from Pedigree 1,
to an average of 31.86 coverage. In the 42 Mb of candidate
regions defined by our linkage results, 95% of the exonic sequence
was covered at a depth of .106. We also sequenced eight
unrelated controls and used data available from dbSNP. In the
7p14.1 (14 RefSeq genes), 8q24.1 region (27 RefSeq genes), 2p25
region (20 RefSeq genes), 5q12.1 region (7 RefSeq genes), and
9q31.1–q33.1 (71 RefSeq genes) regions we found no variants
unique to the patient genome with a high likelihood of functional
significance (stops gained and frameshifting indels). However, in
the 12q23 region (105 RefSeq genes), we identified one
frameshifting indel, an 11 bp deletion extending to but not
including the 39 base in exon 4 of PTPN11 (c.514_524del11, see
Supplementary Figure 4 in Text S1). This deletion shifts the
reading frame, leading to a new sequence of 12 codons followed by
a premature stop codon. We verified these results by direct Sanger
sequencing of the PTPN11 exon 4 amplicon.
Author Summary
Metachondromatosis (MC) is an autosomal dominant
condition characterized by exostoses (osteochondromas),
commonly of the hands and feet, and enchondromas of
long bone metaphyses and iliac crests. MC exostoses may
regress or even resolve over time, and short stature is not
characteristic of MC. Here, we sequenced the whole
genome of a single patient with MC and used partial
linkage data from her small family to focus our search for
the responsible variant. In the proband, we identified an
11 bp deletion in exon four of PTPN11, which results in
premature translation termination and co-segregates with
the phenotype. In a second metachondromatosis family,
we identified a nonsense mutation in exon 4 of PTPN11
that also co-segregates with the phenotype. Germline
gain-of-function missense mutations in PTPN11 cause an
overlapping but distinct group of dominant disorders with
involvement of the face, heart, skeleton, skin, and brain,
including Noonan syndrome (OMIM 163950), Noonan-like
disorder with multiple giant cell lesion syndrome (OMIM
163955), and LEOPARD syndrome (OMIM 151100). Non-
sense mutations in PTPN11 have not been described in
humans and the loss-of-function PTPN11 mutations we
report here are the first to be described in human disease.
Sequencing of Proband Identifies Disease Gene
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We confirmed the segregation of the PTPN11 deletion with the
affected status in members of Pedigree 1 using a PCR assay
(Supplementary Figure 3 in Text S1); all affected members carried
the deletion. Additionally, one apparently unaffected individual
(III-1), the same individual that was scored as non-penetrant in the
linkage analysis, was also heterozygous for the PTPN11 deletion.
After obtaining these results, we had the opportunity to examine
III-1 and found that she was affected with bilateral internal
exostoses of her mandible and that her daughter (IV-1) was also
affected with an exostoses of her right proximal tibia.
These WGS results together with the segregation analysis
suggested that the PTPN11 deletion was responsible for MC in
Pedigree 1. To test this hypothesis, we identified a second family
Figure 1. Manifestations of metachondromatosis. (A) Dorsal view of the right hand of individual III-2 in Pedigree 2 at age 12 years, with residual
exostoses following partial surgical removal over the metacarpophalangeal (MCP) joint of the second digit and primary exostoses of MCP of the fifth
digit. (B) Dorsal view of the right hand of individual V-1 in Pedigree 1 at three years, showing deformity of the second digit secondary to exostoses of
the middle phalanx and an exostoses over the middle phalanx of the fourth digit. (C) Radiograph of the dorsal view of the right hand of individual V-1
in Pedigree 1 at three years.
doi:10.1371/journal.pgen.1000991.g001
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(Figure 2B). We sequenced all PTPN11 exons and flanking splice
sites in individual III-4 of Pedigree 2 and found a heterozygous
nonsense mutation, p.R138X, resulting from a C to T transition at
position 111,375,382 in exon 4. This mutation abolishes the
recognition site for RsaI, and we used PCR amplification of
PTPN11 exon 4, followed by restriction of the amplicon with RsaI,
to follow the segregation of p.R138X in members of Pedigree 2.
All affected individuals were p.R138X heterozygotes, as were two
apparently unaffected individuals, II-2 and II-4, who were adults
when examined. These results are consistent with the conclusion
that this nonsense mutation is responsible for MC in affected
individuals in pedigree 2, with non-penetrance in individuals II-2
and II-4, both of whom have affected children.
As a further test of the significance of the mutations we
identified, we amplified and successfully Sanger sequenced
PTPN11 exon 4 in 469 control, unrelated individuals of whom
60% were of European descent similar to that of our two affected
families, 11% were African-American, 11% were East Asian and
18% were of other ethnicities. We found no examples of either of
these mutations, nor any other variants in exon 4 predicted to
result in the loss of PTPN11 function.
Discussion
PTPN11 encodes the protein tyrosine phosphatase SHP-2,
which is an src homology-2 (SH2)-containing protein tyrosine
phosphate (PTP) that is highly conserved among metazoans and
Figure 2. Pedigrees. Of families 1 (A) and 2 (B). The red arrow indicates the proband in each family. Segregation of the causal variant with the
disease is shown in each family. Although III-1 and IV-1 in pedigree 1 were originally reported to be unaffected, we had the opportunity to examine
them during the preparation of this manuscript and found that both had exostoses.
doi:10.1371/journal.pgen.1000991.g002
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several receptor tyrosine kinases including EGFR and FGFR [16].
The N-terminal half of SHP-2 contains two SH2 domains (N-SH2
and C-SH2), while the C-terminal half contains the catalytic PTP
domain. SHP-2 is ubiquitously expressed. Activation of SHP-2 has
a positive effect on RAS/MAPK signal transduction in most
contexts. Germline gain of function missense mutations in PTPN11
cause an overlapping but distinct group of dominant disorders
with involvement of the face, heart, skeleton, skin and brain,
including Noonan syndrome (OMIM 163950), Noonan-like
disorder with multiple giant cell lesion syndrome (OMIM
163955) and LEOPARD syndrome (OMIM 151100) [17,18].
Nonsense mutations in PTPN11 have not been described in
humans, but in mice a gene-targeted mutant Ptpn11 allele that
deletes codons 46–110 is an early developmental recessive lethal
[19,20]. No phenotype was described in the heterozygotes, but the
murine counterpart of MC could easily be overlooked and it would
be useful to re-examine Ptpn11+/2 mice [20]. The loss of function
PTPN11 mutations we report here (c.514_524del11 and p.R138X)
are the first to be described in human disease. Not surprisingly,
MC has essentially no phenotypic overlap with the other disorders
caused by PTPN11 mutations, with the possible exception that one
affected individual in Pedigree 2, I-2, a 71-year-old male, has
multiple truncal lentigenes (Supplementary Figure 1 in Text S1).
How, or if, this is explained by a pathophysiologic overlap with the
more extensive and earlier age of onset lentigenes characteristic of
the LEOPARD syndrome is not clear.
Incomplete penetrance is a well-described feature of MC and
many other dominant disorders and complicates co-segregation
tests of candidate causative mutations. Interestingly, in Pedigree 1,
individual III-1 was initially reported as unaffected and her status
influenced our linkage analysis. However, during the preparation
of this manuscript, we had our first opportunity to examine III-1.
She has bilateral, internal exostoses of her mandible. Thus, her
original classification as non-penetrant was incorrect.
Our results suggest that PTPN11 and other members of the
RAS/MAPK pathway should be examined in related and as yet
unexplained Mendelian phenotypes such as Ollier’s disease,
Mafucci syndrome (OMIM 166000) and the trichorhinophalan-
geal syndrome type II (OMIM150230). Additionally, it is
interesting to speculate on the focal nature and limited duration
of the enchondromas and exostoses in MC. The local nature and
childhood onset of these lesions suggests the possibility that a
second mutational event is required for their appearance, a
possibility that can be tested by examining PTPN11 in these
tumors. The reason for spontaneous regression of some of these
lesions is unclear, but may be due to the developmental
maturation of the affected tissue.
Our study adds to a small but growing list of examples where
genome-wide sequencing approaches have successfully identified
rare, high-penetrant risk factors for disease. Ours is one of the first
to take the whole-genome approach, although the variant we
identified would have been found using either WGS or WES.
However, two key distinguishing features of this study are that
discovery of the disease-causing variant resulted from the initial
sequencing of only a single patient genome and that weak linkage
evidence helped to identify regions most likely to harbor the
causative variant. The linkage evidence present in this family
restricted our search for the causal variant to 42 Mb, which
contained only one protein-truncating variant unique to our
sequenced case. Without this linkage evidence, sifting through the
109 protein-truncating variants unique to this genome (19 stops
gained, 90 frameshifting indels) to find the causal variant would
have been a difficult task. It would also have been difficult to sift
through the many unique variants in the linked regions if it were
not possible to assess the function of all identified variants, whether
previously known or novel as the one we found. We also note that
generating the necessary sequence data for all genes in the 42 Mb
implicated region in the first family would be a daunting task using
traditional sequencing approaches. This paradigm of WGS with
the prioritization of variants by predicted functional consequence
and frequency in controls combined with information gleaned by
classical genetic approaches should prove effective for other
unexplained Mendelian phenotypes and may also prove effective
in the study of more common diseases that show modest linkage
evidence.
Materials and Methods
Informed consent was obtained through a Johns Hopkins
Medical Institutions IRB approved protocol and a Duke
University IRB approved protocol.
Individuals with MC from two families were identified and
recruited from the Johns Hopkins Hospital Genetics Clinic.
Informed consent was obtained through a Johns Hopkins Medical
Figure 3. Plot of linkage results from Pedigree 1. The regions investigated for causal variants were 7p14.1, 8q24.1, 12q23, 2p25, 5q12.1, and
9q31.1–q33.1.
doi:10.1371/journal.pgen.1000991.g003
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generation family comprised of 12 individuals for whom we had
DNA. Seven individuals were classified as ‘‘affected’’ and five were
‘‘unaffected’’. Family 2 was a three-generation family of three
‘‘affected’’ individuals and seven ‘‘unaffecteds’’ for whom we had
DNA.
In preparation for interpreting the results of our WGS, we
performed linkage analysis on Pedigree 1 (Figure 2A) by
genotyping 7 family members using the Illumina HumanHap
550 Genotyping BeadChip v1.0 and 5 family members with
Illumina Human 610-Quad v1.0 Genotyping BeadChip. We
selected ,2% of the genotyped SNPs (10,763 autosomal SNPs),
requiring that they were heterozygous in at least 4 genotyped
individuals, and used them for parametric linkage as calculated
with the Merlin linkage analysis software [21] assuming a
dominant model with reduced penetrance (set at 0.8). We also
analyzed allele sharing and determined non-penetrant individuals
using the tools pediSNP and SNPduo (Supplementary Figure 2 in
Text S1). Figure 3 shows the results of the linkage analysis across
all autosomes.
We performed WGS on a single individual (V-1) from MC
pedigree 1 with an Illumina Genome Analyzer II. The sequence
runs were paired-end 75 base pair reads, with 110 billion bases
passing the Illumina analysis filter. To assess overall coverage, all
gaps (stretches of N’s) in the reference genome (Ensembl build 36
release 50) were excluded, resulting in the reference having
2,855,996,286 bases. After accounting for PCR duplicates and
reads that did not align to the reference genome, our genomic
coverage was 31.86. We defined a ‘‘covered’’ base as one with at
least five reads with a Phred-like consensus score greater than zero.
Using these criteria, we covered approximately 97.8% of the
reference genome. We then used data from eight control genomes
that we had sequenced to an average coverage of 35.96 and
dbSNP as filters to remove common variants. To identify
candidate pathogenic mutations, we used SVA (http://www.
svaproject.org/) to group all variants into functional categories.
We expected that the variant responsible for MC would be rare
and would not be found in dbSNP or in the control sequenced
genomes. We also expected that it would be a severe functional
variant, and thus concentrated on those variants that resulted in
protein truncation: nonsense mutations and frameshifting indels.
Supporting Information
Text S1 Supplementary methods and figures.
Found at: doi:10.1371/journal.pgen.1000991.s001 (3.28 MB
DOC)
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